2024-12-05T00:00:00.000+00:00
Ongoing

Fusion Pharmaceuticals

Fusion Pharmaceuticals
Chronic Lymphocytic Leukaemia

A phase 2, open-label, multi-centre study of FPI-2265 (225Ac-PSMA-I&T) and olaparib in participants with metastatic castration-resistant prostate cancer (mCRPC).

A phase 2, open-label, multi-centre study of FPI-2265 (225Ac-PSMA-I&T) and olaparib in participants with metastatic castration-resistant prostate cancer (mCRPC).

Trial overview

Disease

Prostate cancer

Topic

Interventional

Sponsor

Fusion Pharmaceuticals

Description

A phase 2, open-label, multi-centre study of FPI-2265 (225Ac-PSMA-I&T) and olaparib in participants with metastatic castration-resistant prostate cancer (mCRPC).

Study details

Trial status

Opening Spring 2025

Location

Oxford and Windsor :::

Principal Investigator

Dr Philip Camilleri

MD, MRCP, FRCR

Clinical Oncologist

Oxford +1

Dr Nicola Dallas

MBChB, MRCP, FRCR

Clinical Oncologist

Windsor +1